secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2026-01-30T23:59:59+00:00
Accession:  0000872589-26-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q4 rev $3.88B (+3%), GAAP EPS $7.86; Dupixent +34% to $4.9B
---------------------------------------------------------------------

- Q4 2025 total revenue $3.884B (+3% YoY); GAAP diluted EPS $7.86 (vs $8.06 Q4 2024); non-GAAP EPS $11.44 (vs $12.07).
- Dupixent global net sales (Sanofi) $4.9B in Q4, +34% YoY; full year $17.8B +26%.
- EYLEA HD U.S. net sales $506M (+66%) but total EYLEA franchise fell 28% to $1.1B on competition and patient transition.
- FDA approved EYLEA HD for RVO and monthly dosing; new vial filler approved; Libtayo approved as first immunotherapy for adjuvant CSCC.
- 2026 guidance: GAAP R&D $6.45-6.68B, non-GAAP gross margin 83-84%; quarterly dividend raised to $0.94/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/0000872589-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/regn-20260130.htm
  HTML page:      https://secwatch.observer/filing/0000872589-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer